Belarus Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports

Belarus Pharmaceuticals and Healthcare Report

Belarus Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports
Belarus Pharmaceuticals and Healthcare Report
Published Aug 06, 2016
75 pages — Published Aug 06, 2016
Price US$ 1,295.00  |  Buy this Report Now

About This Report

  
Abstract:

On June -- ----, President Lukashenko announced that the modernisation of healthcare infrastructure will be completed during the next five years in the state s --------- vision. In April ----, the Ministry of Health announced changes to the existing pricing mechanism for medicines: the maximum wholesale and retail mark-ups are no longer to be set to the dollar; this will prevent price instability and keep costs at an affordable level. ...On June -- ----, President Lukashenko announced that the modernisation of healthcare infrastructure will be completed during the next five years in the state s --------- vision. In April ----, the Ministry of Health announced changes to the existing pricing mechanism for medicines: the maximum wholesale and retail mark-ups are no longer to be set to the dollar; this will prevent price instability and keep costs at an affordable level. The ruble has depreciated significantly to the dollar in recent years, leading to drug prices increasing. ...The ruble has depreciated significantly to the dollar in recent years, leading to drug prices increasing. In March ----, Health Minister Vasily Zharko stated his intentions to develop a voluntary health insurance system, noting that this would reduce the financial burden on health services.

...In BMI s Q--- Pharmaceutical Risk/Reward Index (RRI) Belarus is ranked --th out of the -- markets in the Central and Eastern European (CEE) matrix with an unchanged score of --.- compared with the previous quarter. Belarus scores considerably below the regional average score of --.- in Q---. ...Belarus scores considerably below the regional average score of --.- in Q---. Despite high sector value growth, the country s Rewards score is below the regional average on account of its low pharmaceutical expenditure. Belarus total score is limited by its economic instability and unfavourable pharmaceutical regulatory environment. ...Despite high sector value growth, the country s Rewards score is below the regional average on account of its low pharmaceutical expenditure. Belarus total score is limited by its economic instability and unfavourable pharmaceutical regulatory environment.

...Economic recession has seen negative growth in the market in both US dollar terms and euro terms. Reimbursement restricted to products bought in state pharmacies and hospitals. ...

  
Source:
Document ID
2040-5030
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Business Monitor International - Industry Reports—Established in 1984, Business Monitor International is a leading online publisher of specialist business information on global emerging markets. Business Monitor's range of quarterly services covers political risk, finance, macroeconomic performance, outlook and forecast, industry sectors and the business operating environment. Each Industry Report has been researched at source, and features latest-available data covering production, sales, imports and exports; 5-year industry forecasts through end-2012; company rankings and competitive landscapes for multinational and local manufacturers and suppliers; and analysis of latest industry developments, trends and regulatory changes.

About the Author


Cite this Report

  
MLA:
Business Monitor International - Industry Reports. "Belarus Pharmaceuticals and Healthcare Report" Aug 06, 2016. Alacra Store. Dec 11, 2016. <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Belarus-Pharmaceuticals-and-Healthcare-Report-2026-2182>
  
APA:
Business Monitor International - Industry Reports. (2016). Belarus Pharmaceuticals and Healthcare Report Aug 06, 2016. New York, NY: Alacra Store. Retrieved Dec 11, 2016 from <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Belarus-Pharmaceuticals-and-Healthcare-Report-2026-2182>
  
US$ 1,295.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.